Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.
Open Access
- 4 April 2001
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 93 (7) , 557-9
- https://doi.org/10.1093/jnci/93.7.557
Abstract
The proto-oncogene human epidermal growth factor receptor 2 (HER2) is a transmembrane glycoprotein with tyrosine kinase activity and, among other functions, controls cellular proliferation. Overexpression of HER2 has been observed in many solid tumors, including 20%–30% of breast cancers (1) and 19%–59.4% of epithelial ovarian cancers (2), and is a predictive marker for response in breast cancer (3,4).Keywords
This publication has 6 references indexed in Scilit:
- Re: Population-Based, Case-Control Study of HER2 Genetic Polymorphism and Breast Cancer RiskJNCI Journal of the National Cancer Institute, 2000
- Population-Based, Case-Control Study of HER2 Genetic Polymorphism and Breast Cancer RiskJNCI Journal of the National Cancer Institute, 2000
- Prognostic relavance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapyBreast Cancer Research and Treatment, 2000
- The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cellsOncogene, 1997
- An EcoRl polymorphism at the insulin receptor locus on a fragment comprising exons 4 to 8Nucleic Acids Research, 1991
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987